source
- BMS reports fatal septic pneumonia in MS patient during CAR T trial of zolacabtagene autoleucelBMS disclosed that a participant in its Phase 1 Breakfree-2 study of the CAR T cell therapy zolacabtagene autoleucel died from septic pneumonia. The patient, who had highly active relapsing multip…
- Novartis MS drug remibrutinib cuts relapse rates by about a third in Phase 3 trialsData presented at an MS conference in Toronto showed that Novartis' experimental therapy, remibrutinib, reduced the annualized relapse rate in relapsing‑remitting multiple sclerosis by roughly 35%…